Ketamine for Treatment-Resistant Depression
Neurobiology and Applications
- 1st Edition - September 16, 2020
- Latest edition
- Editors: Gustavo H. Vazquez, Carlos A. Zarate, Elisa Brietzke
- Language: English
Ketamine for Treatment-Resistant Depression: Neurobiology and Applications provides a simple, evidence-based overview for neuropsychiatrists and translational researchers on this m… Read more
Description
Description
Ketamine for Treatment-Resistant Depression: Neurobiology and Applications provides a simple, evidence-based overview for neuropsychiatrists and translational researchers on this medication, its mechanisms of actions, eligibility of patients for treatment, and the preparation and implementation of ketamine clinics.
Key features
Key features
- Provides efficacy research on ketamine as a treatment for depression
- Identifies best practices for clinical use, both long-term and acute
- Discusses the molecular mechanisms and neurobiology of action
Readership
Readership
Neuropsychiatrists and translational researchers, nursing staff, students and administrators
Table of contents
Table of contents
1. Ketamine, Clio, and the hippocratic triangled fragments of the history of ketamine
2. Ketamine’s potential mechanism of action for rapid antidepressive effects – a focus on neuroplasticity
3. Treatment resistant depression
4. Suicide in psychiatric disorders: rates, risk factors, and therapeutics
5. Overview of ketamine for major depression: efficacy and effectiveness
6. How to implement a ketamine clinic
7. Development of new rapid-action treatments in mood disorders
8. Closing remarks
2. Ketamine’s potential mechanism of action for rapid antidepressive effects – a focus on neuroplasticity
3. Treatment resistant depression
4. Suicide in psychiatric disorders: rates, risk factors, and therapeutics
5. Overview of ketamine for major depression: efficacy and effectiveness
6. How to implement a ketamine clinic
7. Development of new rapid-action treatments in mood disorders
8. Closing remarks
Review quotes
Review quotes
"This is the first book that specifically focuses on ketamine for treatment-resistant depression. This topic has been covered in lectures, articles, and briefly in some textbooks, but this is the first book I have read that specifically covers it. Given the limited available data, the book succeeds in its stated goal to inform readers about what is currently known about ketamine. Updated editions will be needed to reflect the growing knowledge base and eventual treatment strategies using ketamine."—© Doody’s Review Service, 2020, Aaron Plattner, MD(Pine Rest Christian Mental Health Services), reviewer, expert opinion
Product details
Product details
- Edition: 1
- Latest edition
- Published: September 16, 2020
- Language: English
About the editors
About the editors
Gustavo H. Vazquez
Editor
Gustavo H. Vazquez is a Full Professor at the School of Medicine, Queen's University, Director of the CME and staff member of the Mood Disorders Research and Treatment Service, Department of Psychiatry, Providence Care Hospital, Kingston, ON, Canada. He is a member of the Centre for Neuroscience Studies (CNS) at Queen's University (Kingston, Canada), member of the Centre of Neurosicence at Palermo University (Buenos Aires, Argentina) and member of the International Consortium for Psychotic and Bipolar Disorders Research at McLean Hospital, Harvard Medical School (Boston, United States of America).
Affiliations and expertise
Professor and Lead, Ketamine Clinic, Mood Disorders Research and Treatment Service, Queen’s University Medical School, Department of Psychiatry, Providence Care Hospital, Kingston, ON, CanadaCarlos A. Zarate
Editor
Carlos A. Zarate, MD, is Chief of the Experimental Therapeutics and Pathophysiology Branch at the National Institute of Mental Health. He is a fellow of the American College of Neuropsychopharmacology and member of the Society of Biological Psychiatry and the Society for Neuroscience. Dr. Zarate’s research focuses on the pathophysiology and development of novel therapeutics for treatment-resistant mood disorders as well as the study of biomarkers and neural correlates of treatment response.
Affiliations and expertise
Chief of the Experimental Therapeutics and Pathophysiology Branch at the National Institute of Mental Health, NIH, Bethesda, MD, USAElisa Brietzke
Editor
Elisa Brietzke is a Psychiatrist and Professor at the Department of Psychiatry of Queen's University School of Medicine in Kingston, ON, Canada. She is attending psychiatrist at the Inpatient Unit from Kingston General Hospital and at Mood Disorders Research and Treatment Unit at Providence Care Hospital, both in Kingston, ON, Canada. Dr. Brietzke is also a member of the Centre for Neuroscience Studies (CNS) at Queen's University. She is a member of the Board of Councillors from the International Society of Bipolar Disorders (ISBD). The focus of her research is neurobiology and innovative interventions on mood disorders. She was awarded by a L'Oreal For Women in Science Award 2015 for her work on premature aging and inflammation in mood disorders.
Affiliations and expertise
Professor, Department of Psychiatry, Queen's University School of Medicine; Attending Psychiatrist, Inpatient Unit, Kingston Health Sciences Centre; Attending Psychiatrist, Mood Disorders Research and Treatment Unit, Providence Care Hospital, Kingston, ON, CanadaView book on ScienceDirect
View book on ScienceDirect
Read Ketamine for Treatment-Resistant Depression on ScienceDirect